More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
|Articles|May 18, 2012
ASCO '12 Abstract Dump: Cancer Stocks in Focus
Advertisement
Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.
_
(AVEO)
(EXEL
_
(ARRY)
Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Aveo Pharmaceuticals and Exelixis, and randomized phase II studies of drugs discovered by Array BioPharma.
Read the full story:
Source: The Street
Advertisement
Related to this article
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
3
How ID, HIV Clinicians Can Influence Policy in an Election Year
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5